Find organisations and helplines in your country:

What Remission Means: Treatment Targets

What response, remission and healing mean, and the treatment targets international IBD experts agreed in 2021.

Doctors use “remission” for more than one thing. Feeling well again, blood and stool tests coming back to normal, and the bowel lining healing can happen at different times, and IBD teams look for each of them. Many IBD teams work towards agreed goals, step by step, and check along the way whether treatment is reaching them. This is often called “treat to target”.

The targets most teams refer to come from STRIDE-II, a set of recommendations agreed by an international panel of IBD experts (the International Organization for the Study of IBD) and published in 2021. They were written for IBD teams. This page explains them in plain words; it doesn’t say what your own targets should be. Your IBD team sets those with you, and can explain where you are now.

Short term: response

The first target is a response: symptoms clearly getting better.

  • Crohn’s disease in adults: tummy pain and the number of runny or very soft stools each day both down by at least half. These two items make up the CDAI-PRO2.
  • Ulcerative colitis in adults: rectal bleeding and the number of stools each day both down by at least half (the bleeding and stool items of the partial Mayo score).
  • Children and teenagers: a fall of at least 12.5 points in the PCDAI or 17.5 in the wPCDAI for Crohn’s disease, or 20 in the PUCAI for ulcerative colitis.

Medium term: remission

Next comes clinical remission, meaning symptoms have settled:

  • Crohn’s disease in adults: an average tummy pain score of 1 or less (on the CDAI’s scale of 0 to 3) and 3 or fewer runny or very soft stools a day, or a Harvey-Bradshaw Index under 5.
  • Ulcerative colitis in adults: no rectal bleeding and a normal number of stools, or a partial Mayo score under 3 with no item scoring more than 1.
  • Children and teenagers: a PCDAI under 10 (under 7.5 when the height item is left out) or a wPCDAI under 12.5 for Crohn’s disease, or a PUCAI under 10 for ulcerative colitis.

The tests that show inflammation should also come down at this stage: C-reactive protein (CRP), a blood test, within the normal range printed on your lab report, and faecal calprotectin, a stool test, down to about 100 to 250 micrograms per gram.

Long term: healing

The long-term targets are:

  • Healing of the bowel lining, seen at a colonoscopy. For Crohn’s disease, that means no ulcers, or an SES-CD under 3. For ulcerative colitis, it means a Mayo endoscopic subscore of 0 (see the full Mayo score), or a UCEIS of 1 or less.
  • Normal growth in children and teenagers.
  • A normal quality of life, without disability from IBD.

STRIDE-II treats response and remission as steps on the way, not as long-term targets on their own.

Deeper healing

Some tests can show healing beyond what a colonoscopy sees. In ulcerative colitis, biopsies (tiny samples of the lining) can show whether inflammation has gone under the microscope. In Crohn’s disease, which can affect the whole thickness of the bowel wall, a scan (MRI, CT or bowel ultrasound) can show whether the wall has healed. STRIDE-II doesn’t set these as targets, but says they can add to the picture.

Why the targets matter for treatment

For most targets, STRIDE-II asks IBD teams to review treatment if the target hasn’t been reached in the expected time. The expected time differs between medicines. So a result that misses a target is something to talk through with your IBD team. Don’t stop or change an IBD medicine on your own.

Questions about your results

If you’re not sure which target you’re working towards, or how close your latest results are, your IBD team or IBD nurse can explain. Your country’s IBD charity also has information on treatment: see the guide to IBD.

Sources